Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Amarin Corporation plc (ADR) (AMRN) Shares Sink on Secondary Offering

Some are skeptical about Amarin’s prospects for obtaining approval to sell Vascepa for treating individuals who have triglyceride levels between 200 and 500 mg/dL. While the drug is approved for people with very high triglyceride levels, the market for this lower-yet-still-high triglyceride level range is 10 times larger.

There is also skepticism in the physician and payer community about the real health benefits of prescription fish-oil drugs. Several clinical studies have had less-than-stellar results.

To be fair, though, studies of Vascepa showed solid results in lowering triglyceride levels. Unlike Glaxo’s Lovaza, it did so without raising cholesterol levels. And while analysts expect Lovaza sales to decline this year, Amarin continues to report higher sales for Vascepa.

AstraZeneca and Omthera only recently submitted a New Drug Application for Epanova in treating patients with very high triglyceride levels of 500 mg/dL and above. Meanwhile, Amarin moves ahead with marketing to that patient population while it awaits possible approval for a much-larger market. A decision by the Food and Drug Administration is scheduled for Dec. 20.

Foolish take
I suspect that the company will continue to report increasing Vascepa sales numbers. There also appears to be a reasonable chance that the FDA will approve the drug for individuals with high (as opposed to very high) triglyceride levels later this year. Amarin’s shares could very well be much higher by year end.

For now, though, I’d recommend a “more means less” strategy. Wait for a little more certainty about the market for Vascepa — and take less profit.

Like many biotech and pharmaceutical stocks, Amarin Corporation plc (ADR) (NASDAQ:AMRN) carries considerable risk. Of course, it also brings the potential for significant rewards in exchange. It’s good for investors to balance stocks like Amarin with others that have less risk, like solid dividend stocks.

The article Amarin Shares Sink on Secondary Offering originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.